MELBOURNE, Australia--(BUSINESS WIRE)--Jan 11, 2021--
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today analyzes pancreatic proenzymes versus T-Cell therapy when targeting
"We are making significant inroads in the way we treat cancer today, but there is a genuine need to continually challenge ourselves to improve the standard of care for many cancer types,"
